Novartis Halts Heart Trial, Touts Positive Phase III Results

Drug Industry Daily
A A
Novartis said Monday it has halted the Phase III trial of its chronic heart failure drug LCZ696 after being notified by a data monitoring committee that the drug met its composite primary endpoint of delayed cardiovascular death and reduced heart failure hospitalizations.

To View This Article:

Login

Subscribe To Drug Industry Daily